Junior Consulting Analyst - Mobility
About the job
- A Bachelor's degree is required.
- Zero to two years of experience in consulting, mobility, transportation, or a related industry is required.
- Strong analytical skills and proficiency in Excel, PowerPoint, and data visualization tools are required.
- Basic knowledge of mobility trends, including public transport, shared mobility, and sustainable transportation, is required.
- Excellent communication and problem-solving skills are required.
- Ability to work collaboratively in a fast-paced environment is required.
- Collect, analyze, and interpret mobility data, industry trends, and customer insights to support consulting projects.
- Assist in developing presentations, reports, and client recommendations based on mobility-sector best practices.
- Collaborate with cross-functional teams to support project delivery and align work with client goals and timelines.
- Identify inefficiencies in mobility services and propose solutions to improve operational performance.
- Stay updated on emerging mobility technologies, including electric vehicles, autonomous vehicles, and smart-city solutions.
- Engage with internal teams and external partners to support project execution and knowledge sharing.
- Experience with data analytics tools such as Tableau, Power BI, or Python.
- Understanding of mobility regulations, policies, and industry frameworks.
- Exposure to project-management methodologies.
About the company
Frost & Sullivan helps large companies pursue growth by providing Strategic Growth consulting and market research. Its core offering, Growth Pipeline as a Service (GPaaS), gives clients a structured process to identify and prioritize growth opportunities, track megatrends, and build a sustainable pathway for expansion. GPaaS works by combining market intelligence, scenario planning, and opportunity prioritization to create a pipeline of actionable growth ideas that executives can invest in. The company differentiates itself from competitors through its long history (over six decades), a disciplined, process-driven approach to uncovering and validating growth opportunities, and a focus on turning insights into a concrete growth agenda rather than just research. Frost & Sullivan’s goal is to help clients achieve transformational, sustainable growth by turning market insights into a clear, executable plan that drives economic value.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Mountain View, California
Founded
1961
Get referred to Frost & Sullivan
See people who can refer or advise you
Simplify's Take
What believers are saying
- The August 27, 2026 Optivara launch monetizes buyers' need to manage AI visibility.
- Janesh Janardhanan's subscriptions mandate expands recurring revenue and cross-sells analytics, reducing project dependence.
- GIL Japan 2026 and Shanghai's 2026 summit deepen lead generation across enterprise buyers.
What critics are saying
- Gartner, Forrester, and IDC commoditize category research, squeezing pricing by 2027.
- OpenAI, Perplexity, and Google AI Overviews reduce discovery for subscription intelligence products.
- If AI answer engines replace analyst searches, Frost's core research franchise loses relevance.
What makes Frost & Sullivan unique
- Frost Radar and Growth Pipeline frameworks convert analyst opinion into buyer-facing benchmarking products.
- The September 2026 Sarwant Singh return strengthens digital platforms, AI advisory, and mobility credibility.
- Sixty-five years of sector coverage and global summits create unusually deep executive relationships.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Health Insurance
Company News
UAE investment drives Middle East biopharma transformation. 7 Oct 2026 21:40 DUBAI (WAM) The UAE is laying the foundations for the Middle East's next phase of biopharma growth, with national investment in genomics, artificial intelligence (AI) and advanced manufacturing reshaping how medicines are discovered, developed and produced across the region. This is according to "From Discovery to Delivery: The Technologies Reshaping Global Biopharma", the first in a new series of exclusive reports by World Health Expo (WHX) in partnership with Frost & Sullivan. The report forecasts growth of more than 10% for precision medicine in the Middle East over the next five to seven years, following a growth trajectory similar to developed markets. The findings point to an increasingly connected regional biopharma ecosystem spanning genomics, next-generation therapies, AI-enabled drug development and local manufacturing. The scale of investment already underway across the UAE is driving this shift. The Emirati Genome Program aims to collect one million genetic samples nationwide, while the UAE Reference Genome study is analysing more than 50,000 genome samples and building infrastructure to support disease prevention, precision treatments and healthcare research. Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) cluster is projected to attract more than Dh42 billion ($11.5 billion) in investment, contribute over Dh94 billion ($25.6 billion) to Abu Dhabi's GDP and create approximately 30,000 jobs by 2045. Spanning biotechnology, pharmaceutical manufacturing, genomics and AI, the cluster reflects the UAE's ambitions to develop capabilities across the biopharma value chain. The report said localisation of pharmaceutical manufacturing is also becoming a strategic priority, highlighting the launch of Mubadala Bio in 2025 to strengthen local manufacturing and pharmaceutical logistics in the UAE. The UAE is also progressing in AI-driven drug discovery and precision medicine. In 2025, Insilico Medicine's Abu Dhabi centre nominated the UAE's first fully AI-discovered preclinical candidates for oncology and non-opioid pain, completing discovery workflows in under 12 months. Further strengthening the emirate's research capabilities, a June 2026 partnership between the Department of Health - Abu Dhabi and Boehringer Ingelheim aims to harness Abu Dhabi's growing genomics infrastructure to advance precision-medicine research. Frost & Sullivan expects expanding local patient databases to create further opportunities for regional and local disease modelling and drug discovery over the next 10 to 15 years. Aarti Chitale, Industry Principal, Healthcare & Lifesciences Growth Analytics at Frost & Sullivan, said: "The biopharma industry is moving towards an increasingly connected model in which precision medicine, AI and advanced manufacturing reinforce one another across the development lifecycle. In the Middle East, and particularly in the UAE, the foundations for that transition are already being built through investment in genomics, digital infrastructure, localisation and global partnerships." She added: "The region's expected double-digit growth in precision medicine over the next five to seven years is particularly significant. As local genomic and patient datasets grow, countries can move beyond adopting technologies developed elsewhere to building homegrown research capabilities, therapies and disease models that better reflect the unique characteristics of regional populations." Frost & Sullivan analysis values the Middle East and Africa pharmaceutical market at $58.66 billion in 2025, accounting for 3.6% of the global pharmaceutical market. The report identifies healthcare reforms and national strategies around biotechnology, AI, digital infrastructure and pharmaceutical manufacturing as significant drivers of the region's future growth. Solenne Singer, Senior Vice President, Healthcare at inD, said: "The findings demonstrate why biopharma has become such an important part of the healthcare growth story in the UAE and the wider Middle East. The UAE is bringing together many of the capabilities required to compete in the next phase of the industry." The report comes as WHX expands its focus on the industries driving healthcare growth. The new Pharma Zone at WHX 2027 will sit alongside the new Biotech Zone and Longevity and Wellness Zone, connecting pharmaceutical manufacturers, contract development and manufacturing organisations (CDMOs), suppliers, distributors, technology providers and commercial partners to support pharmaceutical development, production and market access. Exhibitors in the Pharma and Biotech Zone at WHX 2027 include Aculife, Biosynth, Brooks Pharma Private Limited, Dishman Carbogen Amcis and ProPharma, bringing together pharmaceutical companies from across the industry and enabling them to connect with healthcare buyers, distributors and potential commercial partners. Taking place from to January 25 to 28, 2027 across Dubai Exhibition Centre at Expo City Dubai and Dubai World Trade Centre, WHX is expected to bring together more than 90,000 attendees, 4,200 exhibitors and representatives from over 195 countries. WHX forms part of World Healthcare Week, alongside WHX Tech and WHX Leaders, connecting healthcare trade, digital health and leadership in one city at the same time.
Frost & Sullivan welcomes back Sarwant Singh to accelerate digital innovation and global growth. Industry veteran and futurist returns to advance digital platforms, strengthen advisory capabilities and drive new business opportunities Women Leadership Training LONDON, Sept. 29, 2026 /PRNewswire/ - Frost & Sullivan is pleased to announce the return of Sarwant Singh, an experienced growth strategist, futurist and mobility industry expert, who will play a key role in advancing the company's digital and AI platform strategy, strengthening its industry Practice Areas and accelerating global business growth. Discover more Financial Markets News Business Networking Events With over 30 years of experience leading major advisory and transformation engagements, Sarwant brings extensive strategic consulting expertise, particularly in the mobility, industrial, tech and energy sectors. A recognised futurist specialising in foresight and megatrends, he is also the author of two books, New Mega Trends, sold in over 30 countries, and Innovating to Zero. Sarwant also serves on several corporate and advisory boards, including as a board member of Vasuki, a Rothschild-established fund investing in automotive start-ups globally, and as a non-executive director of Ascenso Tyres. Based in London, Sarwant's priorities will include accelerating the development of integrated digital solutions, notably the Frost Transformation Engine and MetaBrain, strengthening the company's industry capabilities and driving new business development and sales transformation initiatives. Commenting on his return, Sarwant Singh said: "I'm delighted to return to Frost & Sullivan at such an exciting time for the business. As AI and digital platforms reshape the research and advisory industry, Business News This Week has a tremendous opportunity to build on the company's deep industry expertise and global relationships. Women Leadership Training "My focus will be on accelerating our digital platform strategy, strengthening collaboration across our Practice Areas and creating new growth opportunities. I'm particularly looking forward to reconnecting with colleagues and helping deliver innovative, scalable solutions that enable our clients to navigate disruption and achieve sustainable growth." Sarwant's return reinforces Frost & Sullivan's commitment to combining its established research and advisory expertise with technology-enabled solutions to deliver greater client value and accelerate growth worldwide. About Frost & Sullivan Frost & Sullivan, the Growth Pipeline Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. Through Growth Pipeline as a Service, the company provides transformational strategies and best-practice models to identify, prioritise and realise growth opportunities. Media Contact Kristina Menzefricke Marketing & Communications Global Customer Experience Frost & Sullivan [email protected]
Frost & Sullivan has announced the return of Sarwant Singh, a growth strategist and futurist with over 30 years of experience. Based in London, Singh will focus on advancing the company's digital and AI platform strategy, particularly the Frost Transformation Engine and MetaBrain, whilst strengthening industry capabilities and driving business development. Singh, author of New Mega Trends and Innovating to Zero, serves on several corporate boards, including Vasuki, a Rothschild-established fund investing in automotive startups. He brings extensive consulting expertise in mobility, industrial, technology, and energy sectors. Singh said the company has "tremendous opportunity" to build on its industry expertise as AI and digital platforms reshape the research and advisory industry. His return reinforces Frost & Sullivan's commitment to combining research expertise with technology-enabled solutions.
Frost & Sullivan has named Lenovo the 2026 Global Technology Innovation Leader in AI-powered sports event technology. The recognition honours Lenovo's role as FIFA's unified technology partner for the FIFA World Cup 2026, where it developed an end-to-end AI ecosystem spanning edge computing, infrastructure, cloud, and intelligent services. Lenovo's innovations include FIFA AI Pro, an AI-driven analytics platform that gave all 48 competing teams access to petabytes of competition data. The company also deployed an Intelligent Command Center, 3D Digital Avatar technology, and AI-powered broadcasting solutions across the tournament. The award evaluates companies on strategy effectiveness and execution. Frost & Sullivan noted that Lenovo successfully consolidated traditionally siloed venue technologies into a single operational platform whilst supporting more than 600 FIFA operators through an intelligent command environment.
Frost & Sullivan and LeadLeo identify Five Industries shaping China's Next 50 Years of growth. 16 Sep, 2026, 23:00 IST New White Paper examines the long-term transformation of artificial intelligence, intelligent manufacturing, mass consumption, healthcare and semiconductors SHANGHAI, Sept. 16, 2026 /PRNewswire/ - Frost & Sullivan, in partnership with LeadLeo, has released the fifth edition of its White Paper on China's Industrial Development Trends for the Next 50 Years, providing a long-term outlook on the technologies, industries and structural shifts expected to shape China's next phase of economic growth. Set against the new industrial cycle of China's 15th Five-Year Plan, the White Paper examines five strategically important industries - Artificial Intelligence, Intelligent Manufacturing, Mass Consumption, Healthcare and Semiconductors - assessing their evolving competitive landscapes, technology trajectories and future growth opportunities. The research finds that China's industrial development is entering a new phase, moving beyond scale-driven expansion towards higher-value innovation, greater technological self-reliance and increasingly interconnected industrial ecosystems. Five Industries Driving Long-Term Transformation Artificial Intelligence: China's AI ecosystem is evolving rapidly from content generation towards agentic AI, autonomous task execution and interaction with the physical world. Agentic AI, Physical AI and AI for Science (AI4S) are identified as important long-term opportunity areas, with AI increasingly becoming an enabling technology across industries. Intelligent Manufacturing: AI, digital twins, robotics and flexible manufacturing are accelerating China's transition towards higher-value, increasingly autonomous production. Industrial and humanoid robotics, alongside the emerging low-altitude economy, are among the areas expected to create new growth opportunities. Mass Consumption: China's consumer economy is shifting from volume-led expansion towards more personalised, service-oriented and digitally enabled consumption. The White Paper highlights the Self-Indulgence Economy, Longevity Economy and Low-Carbon Consumption as structural opportunities with significant long-term potential. Healthcare: China is moving from generic-drug-led expansion towards original innovation and greater participation in global healthcare markets. Synthetic biology, innovative drug globalisation and AI-enabled medical devices are expected to play increasingly important roles in the development of a more integrated, life-cycle approach to healthcare. Semiconductors: Growing AI computing requirements and changing semiconductor architectures are driving a shift from individual chip substitution towards system-level ecosystem competition. AI chips, AI/HPC packaging, 3D metrology equipment and emerging memory technologies are identified as key areas for future development. The White Paper also examines 10 Chinese business cases spanning AI infrastructure, advanced manufacturing, consumer supply-chain innovation, healthcare technologies and semiconductor development, illustrating how Chinese companies are translating technological advances into new business models and commercial opportunities. Dr. Neil Wang, Global Senior VP, Co-Chairman of Asia Pacific, and Chairman of Frost & Sullivan China, said: "China's next phase of industrial development will be defined not simply by scale, but by its ability to translate technology, innovation and ecosystem capabilities into sustainable growth. This White Paper provides businesses and investors with a long-term view of where that transformation is taking place and the opportunities it is likely to create." About Frost & Sullivan Frost & Sullivan, the Growth Pipeline Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company's Growth Pipeline as a Service provides the CEO's Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. For over 60 years, Frost & Sullivan has partnered with investors, corporate leaders, and governments to identify, prioritize, and execute transformational growth strategies. Media Contact